The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Credits: None available.
As a result of participating in this activity, learners will be able/better able to:
Learn state-of-the-art strategies for intrathecal (IT) drug delivery via nanomedicine.
Nanomedicine-delivered agents allow for new targets and greater efficacy of delivery for therapeutic molecules, imaging agents, and genes to reach the surfaces of the brain and spinal cord. In some cases, evidence suggests that these compounds may reach parenchymal structures.
Several IT nanomedicine have reached clinical trail or been clinically approved for use in humans, and research is into accelerating. IT delivery of nanoparticles has found utility in preclinical models of CNS disease, including pain, neuroinflammation, infection, metabolism, neurotrauma, neurovascular disease, behavior and cancer.
This presentation combines preclinical and clinical literature describing the use of various forms of nanomedicine in an IT context.
Release date: This activity was released 8/27/2021.
Termination date: The content of this activity remains eligible for CME Credit until 8/26/2024, unless reviewed or amended prior to this date.
Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Neurovations Education designates this other activity (blended learning) for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest
[Presenter] Rachael Sirianni discloses the following financial relationships within the past 24 months: Consulting: Ian’s Friends Foundation, Exicure, Inc., Zulia Biotech
No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).
You must be logged in and own this session in order to post comments.
Accreditation & Designation
Neurovations Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Neurovations Education designates this other activity (blended learning) for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity includes discussions of unlabeled or investigational uses of commercial and/or developmental products.
This activity includes discussions and explorations of new and evolving topics. Such inclusion includes adequate justifications of statements based upon current science, evidence and clinical reasoning.
Disclosure of Financial Relationships & Measures to Resolve of Conflicts of Interest
[Presenter] Rachael Sirianni discloses the following financial relationships within the past 24 months: Consulting: Ian’s Friends Foundation, Exicure, Inc., Zulia Biotech
No other person with control of, or responsibility for, the planning, delivery, or evaluation of accredited continuing education has, or has had within the past 24 months, financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships have been mitigated. Materials were reviewed in advance of the activity by person(s) that do not have conflicts of interest related to the content. In some cases, content may have been modified as part of the review and mitigation process. All clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines).